Chemed Corporation (NYSE:CHE) Receives Consensus Recommendation of “Hold” from Analysts

Chemed Corporation (NYSE:CHE) has earned a consensus rating of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $530.75.

Several equities research analysts recently commented on CHE shares. Oppenheimer raised their target price on Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Chemed from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Royal Bank Of Canada raised their price target on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th.

Insider Activity

In other Chemed news, Director Andrea R. Lindell sold 1,347 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. This represents a 22.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick P. Grace sold 190 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $532.00, for a total value of $101,080.00. Following the completion of the sale, the director directly owned 3,533 shares of the company’s stock, valued at $1,879,556. This trade represents a 5.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,537 shares of company stock worth $1,782,654 in the last three months. Company insiders own 3.33% of the company’s stock.

Institutional Trading of Chemed

Hedge funds have recently bought and sold shares of the business. TD Asset Management Inc increased its holdings in Chemed by 7.5% during the 4th quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock worth $138,860,000 after purchasing an additional 22,715 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Chemed by 14.5% during the fourth quarter. BNP Paribas Financial Markets now owns 35,024 shares of the company’s stock worth $14,985,000 after buying an additional 4,430 shares in the last quarter. Epoch Investment Partners Inc. raised its position in Chemed by 4.9% in the 4th quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company’s stock valued at $137,945,000 after buying an additional 15,133 shares during the last quarter. Abacus FCF Advisors LLC bought a new position in Chemed during the 4th quarter valued at $5,935,000. Finally, C WorldWide Group Holding A S purchased a new position in Chemed during the 4th quarter worth $2,189,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Price Performance

Shares of NYSE CHE opened at $541.33 on Monday. The company has a market capitalization of $7.08 billion, a PE ratio of 27.19, a P/E/G ratio of 2.05 and a beta of 0.51. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17. Chemed has a twelve month low of $365.20 and a twelve month high of $557.00. The firm has a fifty day simple moving average of $499.24 and a 200 day simple moving average of $446.50.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The business had revenue of $673.25 million for the quarter, compared to analysts’ expectations of $665.04 million. During the same quarter in the prior year, the firm posted $4.27 earnings per share. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, sell-side analysts forecast that Chemed will post 23.18 EPS for the current year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be given a dividend of $0.70 per share. This is a boost from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Monday, August 17th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s payout ratio is currently 14.06%.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.